Our theme aims to progress understanding of acute, multi-organ involvement in rare haemostasis disorders with significant morbidity and mortality, and revolutionise blood transfusion using genetic blood typing, making transfusions safer, particularly for our multi-transfused, multi-ethnic communities with haemoglobinopathies.
Our partnership with the University provides our theme a strong foundation in fundamental science, but we also work closely with patients and volunteers, including very large national longitudinal studies, international consortia and national health records data.
We also work closely with other BRC specialist themes because of the impact of the immune system on haemostasis, and the role of cellular targets of interest (other ADAMTS-proteins) in coronary artery disease.
For the next 5 years our theme has identified the following priorities/ key strategic and scientific approaches:
- Improving the identification and treatment of immune- mediated Thrombotic Thrombocytopenic Purpura (TTP), preventing relapse and delivering more precise interventions without increasing infections or complications from immunotherapy.
- Modernise blood-matching for those requiring repeated transfusion, using genomics, maximising safety and efficacy with minimal waste.
- Leverage untapped information and data contained in routine blood samples using Artificial Intelligence (AI), to detect both rare and common conditions earlier.
We will focus on:
- Progressing understanding of acute, multi-organ involvement in rare haemostasis disorders with significant morbidity and mortality, exemplified by recent Vaccine-Induced Immune Thrombocytopenia and thrombosis (VITT) and TTP.
- Improving the clinical effectiveness of transfusion by genomic-matching of blood.
- Applying AI to high-dimensional Full Blood Count (FBC) data to enhance the precision of clinical interventions.
